BIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program
|
|
- Jemimah O’Neal’
- 6 years ago
- Views:
Transcription
1 BIOPHARMA SOLUTIONS TM Expedite Your Drug Program
2 Maximize the Value of Your Asset The journey of drug development can be complex stressful. But it doesn t have to be that way. Join more than 600 biopharmaceutical companies each year that partner with Covance to help manage their novel drugs through the development continuum. You get deep expertise applied to your program by working with a team that has managed more than 1,800 unique molecules, 300 enabling programs 125 First-in-Human (FIH) trials in the past five years. w, you can confidently enjoy development efficiency that spans preclinical, clinical commercial phases. Gain insights through solutions specifically designed to meet the needs of biopharma companies that can save you time money while maintaining study quality data integrity. A unique solution that gives you: A dedicated team, with broad therapeutic expertise, that delivers continuity through study concept execution, regulatory submissions clinical trials. A drug development approach that minimizes risk maximizes opportunities. Flexible processes simplified financial options that help you meet the goals milestones of your investors. Get an unprecedented continuity of science, regulatory process strategies throughout your program a CRO partnership experience unlike any other. DISCOVERY DEVELOPMENT COMMERCIALIZATION RESEARCH PRECLINICAL PHASE I PHASE II PHASE III PHASE IV Individual Milestone Solutions Lead Optimization Safety & Efficacy Early Phase Solutions Lead Optimization through PoC Lead Optimization through Enabling Enabling Full Solutions through FIH through PoC FIH PoC Phase III-IV Covance MarketPlace Market Access Regulatory Lead Optimization through Phase IV
3 Optimize Your Probability of Success Put the experience of the world s largest drug development database to work on your program. You have access to a global infrastructure industry-leading nonclinical, regulatory clinical expertise to ensure a tightly aligned, continuous solution to bridge your journey across key development milestones. That s why pharmaceutical biotech companies have named Covance as their preferred partner every stage of development. 1 COVANCE MARKETPLACE matter what phase you are in, you can ge the right connection with potential partners, while safeguarding your asset through a unique networking solution called Covance MarketPlace. LEAD OPTIMIZATION Minimize delays during the nonclinical clinical stages of your drug development program by identifying the right molecule, revealing the one that best minimizes risk. EARLY PHASE DEVELOPMENT SOLUTIONS Get one consistent dedicated drug development team with a single point of contact to advance your program seamlessly from nonclinical through FIH proof-of-concept (PoC ) phases. LATE-STAGE CLINICAL DEVELOPMENT Collaborate with a dedicated management team to efficiently navigate the complexities of drug development, such as simplifying trial protocols, optimizing the selection of trial site location, quickly recruiting the right patient populations, improving trial technology accessing insight from global regulatory experts. CMC SOLUTIONS From analytical testing to life-cycle management, build a strong strategy overcome analytical challenges through Chemistry, Manufacturing Controls support both biologics small molecule programs. CENTRAL LABORATORY SERVICES Tap into the power of the world s leading network of central specialty laboratories to access a wide range of comprehensive solutions. From stard testing to customized assays, you ll receive globally consistent actionable data to meet your study s financial timeline milestones. REGULATORY AFFAIRS Enjoy smooth regulatory approvals with a strategy that addresses audit, submission, publishing post-licensing support. More than 150 regulatory affairs professionals in more than 14 countries are at your service. MARKET ACCESS AND COMMERCIALIZATION Gain a clear understing of your asset s clinical economic value in terms that resonate with payers, providers, patients, investors potential pharma partners. By combining perspectives in safety, efficacy, quality commercial potential, you can quickly reach decision points increase your ROI. 1 Source: Robert W. Baird & Co. survey data.
4 Expedite Your Drug Journey Click on a development phase to view it in greater detail. NON General Tox Target Protocol Dev. Stability Safety / Immuno- Study toxicology IND/ CTA Prep FIH Study Phase I First in Phase IIa Proof of Principle Human (FIH) (PoP)/Proof of Concept (PoC) *Exploratory Trials Recruit- ment Phase IIb PoP/PoC First-in-Human Study Single Ascending Multiple Ascending Proof of Principle (PoP)/ Drug Phase III *Phase IIIb Peri- Phase III Registrational Approval *t all programs will require peri-approval studies., Phase IV /or Peri-approval Registrational Peri-approval Post Markett In Vitro In Vivo Exploratory Tissue Cross Reactivity FIH Study TOX (Chronic Tox ) TOX (DART O al & Reproductive Tox) Biomarker /PD Study ADA Final ADA Validation ADA ADA NAb NAb Dev. Dev. /PD of Samples Immunogenicity (ADA & NAb) Assessment Pharmacokinetic Data Dev. Dev. / Sample / Sample Chemistry, Manufacturing & Controls m Analytics Write Reports Assay Robustness Assessment () Assay Robustness Assessment Pre-Validation Activities/ Perm Support Assay Validation Activities Reports BLA Support/Reports Download Poster Download Brochure Reference Dev. Stard CMC Prep. & n- Batch Record Refinement Prep Formulation Pre-Formulation with Accelerated Stability Prepare Report Meeting Pre-IND SUBMITTED Release ICH Stability Key Intermediates, Drug Product Optimization Final Image Validation Testing Key Intermediates, Meeting PII of End Launch Market BLA/NDA/MAA REPORT PREPARATION Define Commercial Develop Commercial Evidence Develop Commercial Evidence Develop Commercial Evidence QUARTER QUARTER Q2 Q3 YEAR Q4 Q2 / 1 Q1 / / Q3 / Q4 / BLA/NDA/MAA REPORT FINALIZATION Communicate Commercial Value
5 NON Target Reports Assay Robustness Assessment () Write Reference Dev. Stard CMC Prep. & Stability / Study In In Exploratory Vitro Vivo Tissue Cross Reactivity Biomarker /PD Study ADA ADA Validation Final Dev. Dev. Formulation Safety FIH Study Single Ascending n- Phase I First in Human (FIH) *Exploratory General Tox Trials IND/ Protocol Dev. CTA Prep First-in-Human Study FIH Study / Sample Batch Record Refinement Prep Prepare Report Pre-Formulation with Accelerated Stability ADA ADA NAb NAb Dev. Dev. Pre-IND Meeting SUBMITTED Multiple Ascending PoP/PoC TOX (Chronic Tox ) Phase IIa Proof of Principle (PoP)/Proof of Concept (PoC) Proof of Principle (PoP)/ Drug Assay Robustness Assessment Phase IIb TOX (DART O al & Reproductive Tox) /PD of Samples Immunogenicity (ADA & NAb) Assessment Pharmacokinetic Data Chemistry, Manufacturing & Controls m Analytics / Sample Drug Product Optimization Final Image Pre-Validation Activities/ Perm Support *Phase IIIb Peri- Post Phase III Registrational Approval Market *t all programs will require peri-approval studies., Phase IV Peri-approval /or Phase III Registrational Assay Validation Activities Reports BLA Support/Reports Validation Testing Key Intermediates, Peri-approval BLA/NDA/MAA REPORT PREPARATION BLA/NDA/MAA REPORT FINALIZATION Communicate Define Commercial Develop Commercial Evidence Develop Commercial Evidence Develop Commercial Evidence Commercial Value Q3 Q2 / YEAR Q4 1 Q1 / Q2 / Q3 / Q4 / Release ICH Stability Key Intermediates, NON Phase I First in Human (FIH) Click here to return to the full map view. Target / In Vitro In Vivo Stability Study (Dose Tolerance) Exploratory Tissue General Tox Protocol Safety (Can Be Run as Part of ) (Can Be Run as Part of ) FIH Study FIH Study ( Specialists generate as part of IND submission package.) *Exploratory Trials (*Requires Exploratory IND) First-In-Human Study (Average study length approx. 8-9 months.) Single Ascending Multiple Ascending (May include cohort(s) of patients seen in a research clinic a hybrid design. ) TOX (Chronic Tox ) Biomarker /PD Study Final ADA ADA Validation ADA NAb ADA NAb /PD of Samples Immunogenicity (ADA & NAb) Assessment Pharmacokinetic Data / Sample / Sample () Write Reports Assay Robustness Assessment () CMC Reference Stard Release ICH Stability Key Intermediates, n- Refinement Batch Record (1) Formulation Pre-Formulation with Accelerated Stability Prepare Report Drug Product Optimization & Final Image Drug Product Optimization Final Image Meeting Pre-IND SUBMITTED Q3 Q2 / YEAR Q4 1 Q1 / Q2 / Q3 / Q4 / Define Commercial
6 Target / Dev. Study Dev. CMC NON Final Dev. Stability In In Exploratory Vitro Vivo Tissue Cross Reactivity Formulation Safety FIH Study Single Ascending Multiple Ascending n- Refinement Pre-Formulation with Accelerated Stability General Tox Protocol Dev. FIH Study / Sample Prepare Report IND/ CTA Biomarker /PD Study ADA ADA Validation Reference Stard Prep. & ADA ADA NAb NAb Dev. Dev. Write Reports Assay Robustness Assessment () Batch Record Prep Pre-IND Meeting Q3 Q2 / YEAR Q4 1 Q1 / Q2 / Q3 / Q4 / Prep First-in-Human Study SUBMITTED Phase I First in Human (FIH) *Exploratory Trials PoP/PoC TOX (Chronic Tox ) Phase IIa Proof of Principle (PoP)/Proof of Concept (PoC) Proof of Principle (PoP)/ Drug Assay Robustness Assessment Drug Product Optimization Final Image Phase IIb TOX (DART O al & Reproductive Tox) /PD of Samples Immunogenicity (ADA & NAb) Assessment Pharmacokinetic Data Chemistry, Manufacturing & Controls m Analytics Pre-Validation Activities/ Perm Support / Sample Release ICH Stability Key Intermediates, *Phase IIIb Peri- Post Phase III Registrational Approval Market *t all programs will require peri-approval studies., Phase IV Peri-approval /or Phase III Assay Validation Activities Reports Registrational BLA Support/Reports Validation Testing Key Intermediates, Peri-approval BLA/NDA/MAA REPORT PREPARATION BLA/NDA/MAA REPORT FINALIZATION Define Commercial Develop Commercial Evidence Develop Commercial Evidence Develop Commercial Evidence Communicate Commercial Value Phase IIa Proof of Principle (PoP)/ Proof of Concept (PoC) PoP/PoC Proof of Principle (PoP) / (Average study length approx. 12 months.) Phase IIb (Average study length approx months.) Click here to return to the full map view. Drug *Metabolism DDI studies can be done anytime in Phase I, II, or IIb as long as they are completed bee Phase III. TOX (DART al & Reproductive Tox) /PD of Samples Immunogenicity (ADA & NAb) Assessment Pharmacokinetic Data / Sample Assay Robustness Assessment Pre-Validation Activities/Perm Support Release ICH Stability Key Intermediates, Develop Commercial Evidence Develop Commercial Evidence
7 Target / Dev. Study Dev. CMC NON Stability In In Exploratory Vitro Vivo Tissue Cross Reactivity Final Dev. Formulation Safety FIH Study Single Ascending Multiple Ascending n- Refinement Pre-Formulation with Accelerated Stability General Tox Protocol Dev. FIH Study / Sample Prepare Report IND/ CTA Biomarker /PD Study ADA ADA Validation Reference Stard Prep. & ADA ADA NAb NAb Dev. Dev. Write Reports Assay Robustness Assessment () Batch Record Prep Pre-IND Meeting Q3 Q2 / YEAR Q4 1 Q1 / Q2 / Q3 / Q4 / Prep First-in-Human Study SUBMITTED Phase I First in Human (FIH) *Exploratory Trials PoP/PoC TOX (Chronic Tox ) Phase IIa Proof of Principle (PoP)/Proof of Concept (PoC) Proof of Principle (PoP)/ Drug Assay Robustness Assessment Phase IIb TOX (DART O al & Reproductive Tox) /PD of Samples Immunogenicity (ADA & NAb) Assessment Pharmacokinetic Data Chemistry, Manufacturing & Controls m Analytics Drug Product Optimization Final Image Pre-Validation Activities/ Perm Support / Sample Release ICH Stability Key Intermediates, *Phase IIIb Peri- Post Phase III Registrational Approval Market *t all programs will require peri-approval studies., Phase IV Peri-approval /or Phase III Assay Validation Activities Reports Registrational BLA Support/Reports Validation Testing Key Intermediates, Peri-approval BLA/NDA/MAA REPORT PREPARATION BLA/NDA/MAA REPORT FINALIZATION Define Commercial Develop Commercial Evidence Develop Commercial Evidence Develop Commercial Evidence Communicate Commercial Value Phase III Registrational *Phase IIIb Peri-Approval Post Market Phase III, Phase IV /or Peri-approval *t all programs will require peri-approval studies. Click here to return to the full map view. Registrational (Usually requires two. Average study length approx months.) Peri-approval (Timing is highly variable. Health authority sponsor will negotiate scope, size timing of any needed Phase IIIb studies. Sponsor-initiated health economics studies to support commercialization.) TOX (DART al & Reproductive Tox) /PD of Samples Immunogenicity (ADA & NAb) Assessment Pharmacokinetic Data / Sample Assay Validation Activities Reports BLA Support/Reports Release ICH Stability Key Intermediates, Validation Testing Key Intermediates, Drug Product Optimization Final Image sbla/nda/maa Submis ion Develop Commercial Evidence BLA/NDA/MAA REPORT PREPARATION BLA/NDA/MAA REPORT FINALIZATION Communicate Commercial Value
8 Expedite Your Drug Journey Join more than 600 biopharmaceutical companies that partner with Covance each year to help manage their novel drugs through the development continuum. NON Phase I First in Human (FIH) Phase IIa Proof of Principle (PoP)/ Proof of Concept (PoC) Phase III Registrational *Phase IIIb Peri-Approval Post Market Target / In Vitro In Vivo Study (Dose Tolerance) Exploratory Tissue Stability Protocol General Tox Safety (Can Be Run as Part of ) (Can Be Run as Part of ) FIH Study FIH Study ( Specialists generate as part of IND submission package.) *Exploratory Trials (*Requires Exploratory IND) First-in-Human Study (Average study length approx. 8-9 months.) Single Ascending Multiple Ascending (May include cohort(s) of patients seen in a research clinic a hybrid design. ) PoP/PoC TOX (Chronic Tox ) Proof of Principle (PoP) / (Average study length approx. 12 months.) Drug Phase IIb (Average study length approx months.) *Metabolism DDI studies can be done anytime in Phase I, II or IIb as long as they are completed bee Phase III. Phase III Registrational (Usually requires two. Average study length approx months.), Phase IV /or Peri-approval *t all programs will require peri-approval studies. Peri-approval (Timing is highly variable. Health authority sponsor will negotiate scope, size timing of any needed Phase IIIb studies. Sponsor-initiated health economics studies to support commercialization.) TOX (DART al & Reproductive Tox) TOX (DART al & Reproductive Tox) Biomarker /PD Study Final ADA ADA Validation ADA NAb ADA NAb /PD of Samples /PD of Samples /PD of Samples Immunogenicity (ADA & NAb) Assessment Immunogenicity (ADA & NAb) Assessment Immunogenicity (ADA & NAb) Assessment Pharmacokinetic Data Pharmacokinetic Data Pharmacokinetic Data / Sample / Sample / Sample / Sample () Write Reports Assay Robustness Assessment () Assay Robustness Assessment Pre-Validation Activities/Perm Support Assay Validation Activities Reports BLA Support/Reports CMC Reference Stard Release ICH Stability Key Intermediates, Release ICH Stability Key Intermediates, Release ICH Stability Key Intermediates, n- Refinement Batch Record (1) Validation Testing Key Intermediates, Formulation Pre-Formulation with Accelerated Stability Prepare Report Drug Product Optimization & Final Image Drug Product Optimization Final Image Drug Product Optimization Final Image Drug Product Optimization Final Image Drug Product Optimization Final Image Pre-IND Meeting SUBMITTED tend of PII Mee ing BLA/NDA/MAA REPORT PREPARATION BLA/NDA/MAA REPORT FINALIZATION Define Commercial Develop Commercial Evidence Develop Commercial Evidence Develop Commercial Evidence Communicate Commercial Value Q3 Q2 / YEAR Q41 Q1 / Q2 / Q3 / Q4 / Download Poster Learn more at covance.com/thebioexperience Covance Inc., headquartered in Princeton, NJ, USA, is the drug development business of Laboratory Corporation of America Holdings (LabCorp). COVANCE is a registered trademark the marketing name Covance Inc. its subsidiaries around the world. The Americas COVANCE ( ) Europe / Africa Asia Pacific Copyright 2017 Covance Inc. BROBPH
9 Let s begin the conversation that can jump-start your drug development program. Contact your Covance Business Director to learn more about solutions designed specifically biopharmaceutical companies, or visit Covance Inc., headquartered in Princeton, NJ, USA, is the drug development business of Laboratory Corporation of America Holdings (LabCorp). COVANCE is a registered trademark the marketing name Covance Inc. its subsidiaries around the world. The Americas COVANCE ( ) Europe / Africa Asia Pacific Copyright 2017 Covance Inc. BROBPH
EARLY PHASE DEVELOPMENT SOLUTIONS
EARLY PHASE DEVELOPMENT SOLUTIONS Real-world case studies demonstrating accelerated timelines, risk reduction and measurable cost savings are possible Early Phase Development Solutions is a unique drug
More informationTHE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS
THE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS What all developers need to know Alicia Baker Director, Global Regulatory Affairs Strategy, Covance John Carlsen, MHA Vice President,
More informationProof of Concept. Achieve your molecule s full potential
Proof of Concept Achieve your molecule s full potential Table of contents 01 Maximize the value of your molecule 02 Enhance your resources and 03 Increase your speed and efficiency 04 your product s market
More informationEARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS
EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS As a full service contract research organisation performing phase I to IV clinical trials across Europe and the Americas for 40
More informationDRUG DEVELOPMENT TARGET PRODUCT PROFILE
DRUG DEVELOPMENT TARGET PRODUCT PROFILE Template This template provides suggested considerations that may assist biopharmaceutical companies in their decisions as to whether to proceed with a drug development
More informationESTIMATE THE IMPACT OF TIME SAVINGS ON YOUR DRUG DEVELOPMENT PROGRAM, ASSET VALUE AND FINANCIAL COMPANY PERFORMANCE
ESTIMATE THE IMPACT OF TIME SAVINGS ON YOUR DRUG DEVELOPMENT PROGRAM, ASSET VALUE AND FINANCIAL COMPANY PERFORMANCE An Economic Comparison of Programmatic and Transactional Development Models PETER SAUSEN,
More informationFinding the right partner for preclinical into phase I. Facts, Threats & Opportunities
Nuvisan Presentation Outsourcing and Clinical Trials DACH, 9th October 2018 Finding the right partner for preclinical into phase I Facts, Threats & Opportunities 9 October 2018 1 PASSIONATE PEOPLE FOR
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationLAB EXPERTS AT YOUR SIDE Over twenty years of experience
LAB EXPERTS AT YOUR SIDE Over twenty years of experience About us SYNLAB Pharma offers a broad range of laboratory services to the biotechnology, pharmaceutical and cosmetic industries as well as to manufacturers
More informationAccelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective
Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective Imran M. Khan, Ph.D. Division of Psychiatry Center for Drug Evaluation and Research FDA
More informationAT A GLANCE. inventivhealthclinical.com
AT A GLANCE inventivhealthclinical.com 1 Table of Contents OVERVIEW 02 PHASE I-IIA 03 PHASE IIB-III 04 LATE STAGE 05 STRATEGIC RESOURCING 06 BIOANALYTICAL 07 QUALITY ASSURANCE 08 CONSULTING 09 THERAPEUTIC
More informationEarly Phase Education WHITEPAPER. Three major items to consider when moving from preclinical to clinical development
Early Phase Education WHITEPAPER Three major items to consider when moving from preclinical to clinical development Three major items to consider when moving from preclinical to clinical development Dr.
More informationTHERAPEUTIC AREAS CARDIOVASCULAR RESEARCH
THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH PPD S CARDIOVASCULAR TEAM: OPTIMIZING TRIALS AND IMPROVING OUTCOMES APPLYING EXPERIENCE, INNOVATION AND EFFICIENCY IN THE FIGHT AGAINST CARDIOVASCULAR DISEASE
More informationIntroduction to clinical trials Magnus Kjaer
Introduction to clinical trials 2016-01-20 Magnus Kjaer One Definition of Clinical Trial NIH 2014 A research study in which one or more human subjects are prospectively assigned to one or more interventions
More informationEnvigo Corporate & Industry Overview. Rutgers University
Envigo Corporate & Industry Overview Rutgers University Joseph Bedford, Ph.D. Corporate Vice President, Strategic Marketing November 15, 2016 envigo.com 1 Who we are Envigo is a global contract research
More informationRe: Docket No. FDA-2015-D-1246: Draft Guidance on Investigational Enzyme Replacement Therapy Products: Nonclinical Assessment
July 13, 2015 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2015-D-1246: Draft Guidance on Investigational Enzyme Replacement
More informationIntroduction to CMC Regulatory Affairs
Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4
More informationYour bridge to. better medicines
Your bridge to better medicines At a Glance Anapharm Bioanalytics is a client-oriented, GLP-certified, FDA-inspected, GCP-compliant and ANVISA-certified bioanalytical contract research organization (CRO)
More informationAgreed with W. Cornell Graduate Program and Tri-I
Drug Development Course From Molecule to Prescription Weill Cornell Graduate School - Tri-Institutional Therapeutics Discovery Institute ABOUT THIS COURSE This course has been designed in collaboration
More informationPAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey
PAREXEL GENOMIC MEDICINE SERVICES Applying genomics to enhance your drug development journey YOUR JOURNEY. OUR MISSION. Genomic expertise to simplify the route to product approval and maximize patient
More informationCareer Growth Areas in Physiology / Pharmacology
Career Growth Areas in Physiology / Pharmacology Magdalena Alonso-Galicia, PhD Pharmacology Department Forest Research Institute, Inc. Jersey City, NJ 1 Career Growth Areas in BioPharma n Pharmaceutical
More informationKey Activities. Ofer Reizes, Ph.D. Skills Development Director
Key Activities Ofer Reizes, Ph.D. Skills Development Director 1 Key Activities Core Question: What key activities required for your Value Propositions? Key Partners Key Activities Key Resources Value Proposition
More informationMAXIMIZING THE VALUE OF CLINICAL TRIALS DATA: A COLLABORATIVE FRAMEWORK FOR DATA STANDARDS GOVERNANCE FROM DATA DEFINITION TO KNOWLEDGE MANAGEMENT
MAXIMIZING THE VALUE OF CLINICAL TRIALS DATA: A COLLABORATIVE FRAMEWORK FOR DATA STANDARDS GOVERNANCE FROM DATA DEFINITION TO KNOWLEDGE MANAGEMENT PharmaSUG Single Day Event Using Standards, Even for Non-Standard
More informationComparative Study of Regulatory Requirements for Biologics Filing in United States and European Union
Comparative Study of Regulatory Requirements for Biologics Filing in United States and European Union Mr. Shashi Kumar Yadav Assistant Professor Sri Indu Institute of Pharmacy Hyderabad Outline Introduction
More informationCLINICAL DEVELOPMENT SERVICES. Immune-Mediated Inflammatory Diseases
CLINICAL DEVELOPMENT SERVICES Immune-Mediated Inflammary Diseases Table of contents 01 The new inflammation paradigm 02 Solutions for your success 03 An interconnected perspective 04 High-quality data
More informationOptimisation de votre programme de développement
Optimisation de votre programme de développement Cedric Lamy, PhD. Cedric.lamy@crl.com Charles River Overview 65-year history: Founded in 1946, publicly traded (NYSE:CRL) Investment in skilled staff: ~7,500
More informationDr. Earl Dye CMC/GMP Considerations for Expedited Development Programs
Dr. Earl Dye CMC/GMP Considerations for Expedited Development Programs Earl Dye is Director of Technical Regulatory Policy in Genentech s Washington, DC Regulatory Affairs Office, and is the FDA Liaison
More informationDrug Development Services
Drug Development Services Speaker Introduction Nik Burlew Vice President Regulatory and Strategic Development 25 Years in Pharma: Development, MFG and QA. Consulting for the last 13 years primarily to
More informationForesee Pharmaceuticals, Inc.
Foresee Pharmaceuticals, Inc. Rapid Development and Commercialization of a Proprietary Sustained-release Depot Formulation of Leuprolide for the Treatment of Advanced Prostate Cancer PNWBIO Meeting 10
More informationIntroduction to clinical trials
Introduction to clinical trials Definition of a clinical trial A research activity that involves administration of a test treatment to some experimental unit in order to evaluate the treatment. Key words
More informationExploratory IND: a study proposal from Novartis
Exploratory IND: a study proposal from Novartis Rossella Belleli ECD BIOS Novartis 17 Nov 005 Presentation outline What is an exploratory (exp)ind compared to a traditional IND Introduction to traditional
More informationIn Vitro Pharmacology Services
In Vitro Pharmacology Services Simplify Your Drug Discovery Workflow What s What s Inside: Inside: Why DiscoverX Services x GPCR Screening & Profiling x Kinase Screening & Profiling x Safety Screening
More informationRegulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
More informationMay 23, :30 PM-5:00 PM - AUDITORIUM A250. May 9, :30 PM -5:00 PM - AUDITORIUM A-950 May 16, :30 PM-5:00 PM - AUDITORIUM A250
DRUG DEVELOPMENT COURSE - FROM MOLECULE TO PRESCRIPTION WEILL CORNELL GRADUATE SCHOOL - TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE THURSDAYS FROM 3:00PM - 5:00PM AT 1300 YORK AVE, NEW YORK, N.Y.
More informationADCS, WHAT IS INDUSTRY DOING TODAY? AN OVERVIEW
ADCS, WHAT IS INDUSTRY DOING TODAY? AN OVERVIEW Johannes Stanta PhD Scientific Manager, Bioanalysis EBF ADC Training day June 2017 Copyright 2017 Covance. All Rights Reserved ADC Bioanalytical PK Assays
More informationPAREXEL STRATEGIC PARTNERSHIPS. Optimizing relationships for shorter time to market
PAREXEL STRATEGIC PARTNERSHIPS Optimizing relationships for shorter time to market YOUR JOURNEY. OUR MISSION. Delivering a more collaborative and operationally efficient relationship so you can reach your
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationCardinal Health Specialty Solutions. Bringing a new drug to life. Regulatory Sciences
Cardinal Health Specialty Solutions Bringing a new drug to life Regulatory Sciences How we guided a pharma s breakthrough vision to commercial reality The right drug can mean the difference between life
More informationComplex Generics: Charting a new path
White paper Complex Generics: Charting a new path Complex generics offer a lucrative market for drug manufacturers, but only if they can adapt to a more complicated and challenging development process.
More informationINSIGHT-DRIVEN FORMULATIONS DEVELOPMENT
INSIGHT-DRIVEN FORMULATIONS DEVELOPMENT HOW AN INTEGRATED DEVELOPMENT PLATFORM CAN PROVIDE END-TO-END VISIBILITY ACROSS PRE-FORMULATIONS AND FORMULATIONS DEVELOPMENT 1 A considerable amount and variety
More informationConducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development
Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development 2015 AAPS Annual Meeting and Exposition October 28, 2015 Kimberly Raines, Ph.D. Lead Pharmacologist Quality
More information! Background. ! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs) ! Consequences in General
! Background! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs)! 5 Approaches (Table 3) for:! Microdose trials (7.1)! Single-Dose (SD) Trials at Sub-therapeutic Doses or Into the
More informationCTA/NDA Regulatory Landscape in China. Jack Xie, PhD, DABT SOT 2016
CTA/NDA Regulatory Landscape in China Jack Xie, PhD, DABT SOT 2016 Disclaimer The content of the following presentation represents solely author s view and may not reflect any position of Roche or China
More informationRole of Academic Investigators in Drug Development
DTRCS Regulatory Education Seminar, June 12, 2007 Role of Academic Investigators in Drug Development Howard Lee, MD, PhD Associate Adjunct Professor Director, Center for Drug Terminology Sponsor Investigator
More informationFrom Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager
From Discovery to Development of new Drugs. and pitfalls along the way by Kim Dekermendjian, PhD in Medicine BD & Key Account manager The roots of Drug Discovery Before 20 th century the term didn't exists,
More informationPLANNING FOR SUCCESS: A CMC STRATEGY FOR BIOSIMILARS
PLANNING FOR SUCCESS: A CMC STRATEGY FOR BIOSIMILARS Louise Angell Lead Scientist 10th Biosimilars & Follow-On Biologics Congregation 9 th May 2017 Copyright @ 2017 Covance. All rights Reserved Overview
More informationDEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE WHEN COMMERCIALIZING A MEDICINE, IT
More informationPaving the way for Non-Clinical Bioanalytical Partnerships Louise Angell
Paving the way for Non-Clinical Bioanalytical Partnerships Louise Angell Content Overview of non-clinical immunogenicity testing for biologics Regulatory guidance Bioanalytical considerations Risk based
More informationEden Biodesign ebook. Celebrating 10 Years of Success
Eden Biodesign ebook Celebrating 10 Years of Success Eden Biodesign ebook Chapter 1: Overview Chapter 2: Our History Chapter 3: Much More than a CMO Chapter 4: Key Milestones Chapter 5: About Eden Biodesign
More informationHarmonizing clinical trials for Biogenerics. Dr. Akhilesh Sharma M.D.;C Clin. Research & P.V. (UCBC - USA & Luton - UK)
Harmonizing clinical trials for Biogenerics Dr. Akhilesh Sharma M.D.;C Clin. Research & P.V. (UCBC - USA & Luton - UK) Senior Vice President & Global Head Global Medical Affairs (C.M.O) Dr. Reddy's Laboratories
More information3M Drug Delivery Systems. April 26, 2011
3M MDI Manufacturing April 26, 2011 3M Drug Delivery Systems Drug Delivery Systems Overview 3M Drug Delivery Systems is a division of 3M that is dedicated to the development and manufacturing of inhalation
More informationICH S9 -Nonclinical Evaluation for Anticancer Pharmaceuticals: Questions and Answers
ICH S9 -Nonclinical Evaluation for Anticancer Pharmaceuticals: Questions and Answers May 2018 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 Legal
More informationAustrade - Partnering with Australia October Nucleus Network Organisational Overview (Oct 2008)
Austrade - Partnering with Australia October 2008 Nucleus Network is an Early Phase Clinical Trial Specialist Austin Centre for Clinical Studies Alfred Centre for Clinical Studies Clinical Trials Consulting
More informationTranslational Pharmaceutics : a unique platform to accelerate early oncology development
Translational Pharmaceutics : a unique platform to accelerate early oncology development Lisa Clarke-Lens, Associate Director, Oncology Services Quotient Clinical Clinical Operations in Oncology Trials
More informationCell Therapy Product Manufacturing Considerations. July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D.
Cell Therapy Product Manufacturing Considerations July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D. Office of Tissues and Advanced Therapies FDA/CBER Overview Establishing Manufacturing Control Applying
More informationIntegration of FDSS7000 into a modular robotic system for Open Innovation drug discovery
Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery José Manuel Brea & María Isabel Loza BioFarma, Santiago de Compostela DRUG DISCOVERY OPEN INNOVATION CLOSED innovation
More informationQUALITY: ADDING VALUE
QUALITY: ADDING VALUE Marian Mutch MSc. Director Global QA Covance Agenda History of Covance Central Laboratory Services, CLS What is ISO 15189? Why adopt ISO 15189 in an organisation that is already following
More information06/03/2009. Overview. Preclinical Support for Exploratory Phase I Clinical Trials. Micro-dosing IND. Pharmacological Active Single Dose IND
Preclinical Support for Exploratory Phase I Clinical Trials Clive Joseph, DSRD Sandwich Overview Identify the most appropriate development paradigm - traditional vs alternative IND approach Confidence
More informationA Streamlined Data Capture and Exchange Partnership that Delivers Faster Decisions
A Streamlined Data Capture and Exchange Partnership that Delivers Faster Decisions 2011 SAS Health & Life Sciences Conference Michelle Combs, PhD, VP, Clinical Pharmacology Sciences, Celerion Bernd Doetzkies,
More informationFDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010
FDA Public Hearing: Approval Pathway for Biosimilar and Interchangeable Biological Products November 2-3, 2010 1 The Biotechnology Industry Organization Over 1,100 members, including biotechnology companies,
More informationENTREPRENEURIAL OPPORTUNITIES IN LIFE SCIENCE QUALITY & REGULATORY
BIOANALYTICAL SOLUTIONS FOR BIOTHERAPEUTICS AND SMALL MOLECULE THERAPEUTICS ENTREPRENEURIAL OPPORTUNITIES IN LIFE SCIENCE QUALITY & REGULATORY MARCH 15, 2017 AIT BIOSCIENCE, LLC BIOANALYSIS TO SUPPORT
More informationComments and suggestions from reviewer
Comments and suggestions from reviewer Page 1 of 13 Title: WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology: WHO/rDNA_DRAFT/12
More informationContact:: (609) Details please visit our website:
SunGen Pharma aims to create a healthier future for patients while increasing shareholder value through the development and introduction of quality, affordable generic products by experienced, passionate
More informationImplications for Preclinical and Clinical Programs. Novartis Pharmaceuticals Oncology Business Unit June 2, 2011
EU Biosimilarityi il it Guidance Implications for Preclinical and Clinical Programs Shefali Kakar Novartis Pharmaceuticals Oncology Business Unit June 2, 2011 Biologics are more complex than small molecules
More informationToxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development
Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development No. 1 of 10 1. regulates all the drugs products manufactured and sold in the USA. (A) EMEA (B) IND (C) FDA (D) NDA (E) OSHA
More informationSTRATEGIC RESOURCING. inventivhealthclinical.com
STRATEGIC RESOURCING inventivhealthclinical.com 1 Table of Contents OVERVIEW 02 STAFFING 03 MOVING UP THE VALUE CHAIN 04 FUNCTIONAL EXPERTISE Biostatistics and Statistical Programming 05 Clinical Monitoring
More informationDMTC Technology Readiness Levels Guideline
Technology Readiness Levels Technology Readiness Levels (TRLs) are used as standardised numerical indicators of the level of maturity of a technology. The standard TRL definitions are given in Table 1.
More informationSelecting A Right Patient Recruitment Company: The Key To Success
Selecting A Right Patient Recruitment Company: The Key To Success A R T I C L E Toll Free Number: 1-888-987-2691 www.makrocare.com/mcsmo 1 With current global economic uncertainty, intense global competition,
More informationHow Targets Are Chosen. Chris Wayman 12 th April 2012
How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench
More informationWhat can be done from regulatory side?
Federal Agency for Medicines and Health Products (FAMHP) What can be done from regulatory side? 9th Annual ecopa Workshop November 29-30, 2008, Brussels Dr. Sonja BEKEN Non-Clinical Assessor, Registration
More informationIntroduction to Drug Development in Commercializing Biomedical Technology
Introduction to Drug Development in Commercializing Biomedical Technology Kevin W. Hunt, Ph.D. Director of Biopharmaceutical Product Development Office of Technology Development and Head of Translational
More informationNUVISAN GROUP. Our Philosophy
NUVISAN GROUP Our Philosophy 2 EARLY DEVELOPMENT Introduction to Nuvisan Fully integrated Contract Research Organisation headquarted in Neu-Ulm, southern part of Germany. Nuvisan - Early Development Headquartered
More informationCONTRACT RESEARCH SERVICES
1537 NW 65th Avenue Plantation, FL 33313 USA Phone: (954) 321-8988 Fax: (954) 321-9778 info@receptopharm.com www.receptopharm.com ReceptoPharm has installed the pathways to develop, produce and supply
More informationA Potential Innovative CMC Solution: Responding To Public Health Needs With An Accelerated Clinical Pathway A Vaccine Example
A Potential Innovative CMC Solution: Responding To Public Health Needs With An Accelerated Clinical Pathway A Vaccine Example January 2018 Natalie A. Christian Integrated Development and Supply Team Lead
More informationNovartis Business Services HR University Relations. Clinical Sciences and Innovation. Postgraduate Program
Novartis Business Services HR University Relations Clinical Sciences and Innovation Postgraduate Program 2 CLINICAL SCIENCES AND INNOVATION CLINICAL SCIENCES AND INNOVATION 3 The CS&I Postgraduate Program
More informationSTARTING STRONGER IN PHASE I THROUGH IIA
PAREXEL CLINICAL RESEARCH SERVICES: EARLY PHASE STARTING STRONGER IN PHASE I THROUGH IIA Adding value from first-in-human through proof-of-concept YOUR JOURNEY. OUR MISSION. Achieve success through early
More informationPAREXEL ACCESS MANAGED ACCESS PROGRAMS
PAREXEL ACCESS MANAGED ACCESS PROGRAMS Demands are increasing on biopharmaceutical companies developing treatments for unmet diseases to make them available to select patients even before the drug is labeled,
More informationIntertek Melbourn Company Presentation. MIBio 2016
Intertek Melbourn Company Presentation MIBio 2016 November 2016 Global Leader in quality solutions across all industries Innovative and bespoke quality solutions for our clients 24/7 FTSE 100 company in
More informationInternational Consortium For Innovation & Quality in Pharmaceutical Development
International Consortium For Innovation & Quality in Pharmaceutical Development s on Draft Guidance: FDA Draft Guidance: Investigational Enzyme Replacement Therapy Products: Nonclinical Assessment (draft
More informationPresentation Outline
IND Application Process: For The New Clinical Investigator John M. Centanni Department of Medicine University of Wisconsin Presentation Outline Journey from basic to clinical research Introduction to FDA
More informationAn Introduction to Clinical Research and Development
Bay Clinical R&D Services An Introduction to Clinical Research and Development The Complex Process by which New Drugs are Tested in Humans Anastassios D. Retzios, Ph.D. Outline of Presentation What is
More informationClinical Trials How, Why and When? Candidate to Market 16 th May 2012 Kirsty Kwiatkowski
Clinical Trials How, Why and When? Candidate to Market 16 th May 2012 Kirsty Kwiatkowski Agenda Why are clinical trials conducted? History Guidelines and Regulations When are trials conducted? Requirements
More informationStem Cell Research: Identifying emerging high priority policy issues
The state stem cell agency Stem Cell Research: Identifying emerging high priority policy issues Ellen G. Feigal, M.D. SVP, Research and Development National Cancer Policy Summit Washington, DC November
More informationIndustry Perspective: The Challenges and Benefits in using Expedited Regulatory Pathways
Industry Perspective: The Challenges and Benefits in using Expedited Regulatory Pathways Alan Poirier, Pfizer Inc. U.S. Regulatory Policy and Global Intelligence Worldwide Safety and Regulatory American
More informationRapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products
RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products Kevin Kane, Scientific Director, BCP 7 th Annual Global Drug Delivery & Formulation Summit 28 th August
More informationSpeed your time to market with FDA s expedited programs
Regulatory Sciences Expediting drug approval Speed your time to market with FDA s expedited programs The faster way to marketing submission and drug approval for serious conditions and rare diseases In
More informationBetter Portfolio Decisions through Predictive Analytics
Better Portfolio Decisions through Predictive Analytics Speakers Jamie Munro, Global Practice Leader, Portfolio & Licensing, Clarivate Analytics Karthik Subramanian, Competitive Intelligence & Clinical
More informationA drug development crossroad lies ahead
G L O B A L C B O C O S T E F F E C T I V E B I O A N A L Y T I C A L H I G H Q U A L I T Y E A R L Y S T A G E C L I N I C A L T R A N S L A T I O N A L M E D I C I N E H I G H L Y C O M P E T E N T A
More informationAdvancing the Frontiers of mab mixtures
Advancing the Frontiers of mab mixtures...unlocking the power of the immune system Symphogen Corporate Presentation June 216 Symphogen/1 Symphogen Overview Privately held company - 125 employees Headquarters
More informationCommon Regulatory Issues for Stem Cell Products. Christopher A Bravery
Common Regulatory Issues for Stem Cell Products 1 Christopher A Bravery cbravery@advbiols.com Regulation of stem cell therapies Helicopter view: Need to show the product is of an acceptable and consistent
More informationRegulatory Affairs in Life Science
www.topra.org/careers Regulatory Affairs in Life Science Samantha Alsbury, Head of Professional Development, TOPRA ENABLING AND PROMOTING EXCELLENCE IN THE HEALTHCARE REGULATORY PROFESSION What is healthcare
More informationInvestor Presentation. September 2018
Investor Presentation September 2018 Safe Harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties
More informationExplore the World of End-to-End. Integrated Lab Performance
Explore the World of End-to-End Integrated Lab Performance Come explore the largest, wholly owned network of BioPharma dedicated laboratories in the world. Discovery/Pharmacology Pre-Clinical/Early Development
More informationDepartment At-A-Glance
Integrated Site Services Functional Role Integrated Site Services (ISS) includes global and country Start-Up and Regulatory units (RSU) and Integrated Patients & Site Services (IPSS). Our department s
More informationDocket #: FDA-2018-D-3268
Subject: Comment on FDA Draft Guidance for Industry Titled Rare Diseases: Early Drug Development and the Role of Pre-Investigational New Drug Application Meetings Docket #: FDA-2018-D-3268 ARM is an international
More informationClinical Trials Roadmap: A Go-To-Market Guide for Probiotics
Clinical Trials Roadmap: A Go-To-Market Guide for Probiotics Clinical Trials Roadmap: A Go-To-Market Guide for Probiotics Joshua Baisley, B.Sc., Director, Clinical Trials As dietary supplement regulations
More informationPPD LABORATORIES COMPREHENSIVE SERVICES
PPD LABORATORIES COMPREHENSIVE SERVICES PPD_Comprehensive_Brochure2016_SinglePages_FINAL.indd 1 6/9/2016 6:04:02 PM PPD LABORATORIES: GLOBAL INNOVATIVE PROVEN PPD Laboratories combines world-class scientific
More informationTuberculosis Drug Accelerator
Tuberculosis Drug Accelerator Overview of Activities and Portfolio who, why, what, how, by when and where are we now Steve Berthel 1 What is the Tuberculosis Drug Accelerator? The A is a groundbreaking
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationGlobal Development Challenges: Classical and Advanced Therapy Medicinal products
Global Development Challenges: Classical and Advanced Therapy Medicinal products Beatriz Silva Lima imed, Lisbon University and Infarmed,, Portugal CHMP, CAT, SAWP Member and SWP Chair NONCLINICAL STUDIES
More information